Tags

Type your tag names separated by a space and hit enter

A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China.
Pharmacogenet Genomics. 2018 05; 28(5):117-124.PG

Abstract

BACKGROUND

Hyperuricemia and gout have become increasingly prevalent in China. Allopurinol is an effective urate-lowering therapy, but it has severe side effects. HLA-B*5801 is highly associated with the allopurinol-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.

PATIENTS AND METHODS

In this retrospective report, we had genotyped HLA-B*5801 in 253 cases of hyperuricemia and gout patients in a Han population in Shenzhen and analyzed the clinical management of medications.

RESULTS

We found 30 carriers of the HLA-B*5801 allele in 253 cases of hyperuricemia or gout patients in the population (11.9%). Allopurinol was prescribed in both HLA-B*5801-positive and HLA-B*5801-negative groups. The evaluation of four models with or without genetic screening and management of allopurinol or febuxostat indicated that the HLA-B*5801 screening had significant cost benefit for clinical management.

CONCLUSION

For appropriate management and cost-effectiveness, the HLA-B*5801 allele should be screened in all patients with hyperuricemia and gout in the Chinese population.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Department of Endocrinology, Xiangya-Shenzhen Endocrinology and Metabolism Center, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, People's Republic of China.

Department of Endocrinology, Xiangya-Shenzhen Endocrinology and Metabolism Center, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, People's Republic of China.

Department of Endocrinology, Xiangya-Shenzhen Endocrinology and Metabolism Center, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, People's Republic of China.

Department of Endocrinology, Xiangya-Shenzhen Endocrinology and Metabolism Center, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, People's Republic of China.

Department of Endocrinology, Xiangya-Shenzhen Endocrinology and Metabolism Center, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, People's Republic of China.

Functional Genomics Group, Genomic Medicine Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK.

MeSH

AdultAllopurinolChinaCost-Benefit AnalysisFebuxostatFemaleGene FrequencyGenetic TestingGoutGout SuppressantsHLA-B AntigensHumansHyperuricemiaMaleMiddle AgedPrecision MedicineRetrospective StudiesTreatment Outcome

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29642234

Citation

Cheng, Heng, et al. "A Retrospective Investigation of HLA-B*5801 in Hyperuricemia Patients in a Han Population of China." Pharmacogenetics and Genomics, vol. 28, no. 5, 2018, pp. 117-124.

Cheng H, Yan D, Zuo X, et al. A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China. Pharmacogenet Genomics. 2018;28(5):117-124.

Cheng, H., Yan, D., Zuo, X., Liu, J., Liu, W., & Zhang, Y. (2018). A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China. Pharmacogenetics and Genomics, 28(5), 117-124. https://doi.org/10.1097/FPC.0000000000000334

Cheng H, et al. A Retrospective Investigation of HLA-B*5801 in Hyperuricemia Patients in a Han Population of China. Pharmacogenet Genomics. 2018;28(5):117-124. PubMed PMID: 29642234.

* Article titles in AMA citation format should be in sentence-case

TY - JOUR T1 - A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China. AU - Cheng,Heng, AU - Yan,Dewen, AU - Zuo,Xin, AU - Liu,Junying, AU - Liu,Wenlan, AU - Zhang,Youming, PY - 2018/4/12/pubmed PY - 2019/2/26/medline PY - 2018/4/12/entrez SP - 117 EP - 124 JF - Pharmacogenetics and genomics JO - Pharmacogenet Genomics VL - 28 IS - 5 N2 - BACKGROUND: Hyperuricemia and gout have become increasingly prevalent in China. Allopurinol is an effective urate-lowering therapy, but it has severe side effects. HLA-B*5801 is highly associated with the allopurinol-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. PATIENTS AND METHODS: In this retrospective report, we had genotyped HLA-B*5801 in 253 cases of hyperuricemia and gout patients in a Han population in Shenzhen and analyzed the clinical management of medications. RESULTS: We found 30 carriers of the HLA-B*5801 allele in 253 cases of hyperuricemia or gout patients in the population (11.9%). Allopurinol was prescribed in both HLA-B*5801-positive and HLA-B*5801-negative groups. The evaluation of four models with or without genetic screening and management of allopurinol or febuxostat indicated that the HLA-B*5801 screening had significant cost benefit for clinical management. CONCLUSION: For appropriate management and cost-effectiveness, the HLA-B*5801 allele should be screened in all patients with hyperuricemia and gout in the Chinese population. SN - 1744-6880 UR - https://www.unboundmedicine.com/medline/citation/29642234/A_retrospective_investigation_of_HLA_B_5801_in_hyperuricemia_patients_in_a_Han_population_of_China_ DB - PRIME DP - Unbound Medicine ER -